Therapeutics News and Research

RSS

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office has allowed claims in a patent application (US Serial No. 12/550,579) derived from the "Tuschl III" patent series. The allowed claims relate to human microRNA miR-155, a microRNA that is a potential target for immuno-inflammatory indications, and a lead program of the Regulus-GSK Strategic Alliance.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

StemCells second-quarter net loss decreases to $4.61 million

StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

Scientists develop new method to enable drug release inside cancer cells

Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.The new system - the first to utilize a class of porous nanomaterials driven by a magnetic core - has the potential to improve both targeted drug-delivery and magnetic resonance imaging in the treatment of cancer and other diseases.

11 Aug 2010

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement with affiliates of Shire plc pursuant to which Noven will acquire global rights to Daytrana® (methylphenidate transdermal system) from Shire.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Unigene second-quarter revenue decreases to $3.03 million

Unigene Laboratories, Inc. has reported its financial results for the quarter ended June 30, 2010.

10 Aug 2010

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.

10 Aug 2010

Anika second-quarter product revenue increases 56% to $13.7 million

Anika Therapeutics, Inc., a leader in products for tissue protection, healing, and repair, based on hyaluronic acid technology, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Loyola University forms new institute for molecular level disease research

Loyola University Chicago Stritch School of Medicine has formed a new research institute dedicated to understanding the molecular causes of cancer, autoimmune disorders, cardiovascular disease and several other illnesses.

10 Aug 2010

Cardium second-quarter net loss decreases to $0.7 million

Cardium Therapeutics today reported highlights and financial results for its second quarter ended June 30, 2010.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

Therapeutics News and Research

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Repros receives US patent for Androxal

Silence Therapeutics receives patent for RNA silencing method

Entelos receives patent for PhysioLab virtual patient technology

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

StemCells second-quarter net loss decreases to $4.61 million

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

Scientists develop new method to enable drug release inside cancer cells

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Unigene second-quarter revenue decreases to $3.03 million

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Anika second-quarter product revenue increases 56% to $13.7 million

Loyola University forms new institute for molecular level disease research

Cardium second-quarter net loss decreases to $0.7 million

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Repros Therapeutics second-quarter net loss decreases to $1.3 million

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News